8-K: Scholar Rock Reports Positive Clinical Trial Progress and Second Quarter 2024 Financial Results

Scholar Rock announced its second quarter 2024 financial results and provided updates on its clinical programs, including positive long-term data for its SMA treatment and progress in its obesity program.

Summary

• Scholar Rock reported a net loss of $58.5 million for the second quarter of 2024, compared to a net loss of $37.9 million for the same period in 2023.
• The company's research and development expenses increased to $42.4 million, up from $26.9 million in the prior year's quarter, primarily due to clinical trial and employee compensation costs.
• General and administrative expenses also rose to $17.1 million from $12.2 million year-over-year, driven by increased employee-related costs.
• As of June 30, 2024, Scholar Rock had approximately $190.5 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2025.
• The company is on track to report topline data from the Phase 3 SAPPHIRE trial for its SMA treatment, apitegromab, in the fourth quarter of 2024.
• Long-term data from the Phase 2 TOPAZ extension study showed sustained clinical benefit over 48 months for patients with nonambulatory SMA, with a patient retention rate of over 90%.
• The Phase 2 EMBRAZE trial for apitegromab in obesity is enrolling ahead of schedule, with topline data expected in the second quarter of 2025.
• Preclinical data for SRK-439, a novel myostatin inhibitor, suggests it could help patients retain lean muscle mass during weight loss and after withdrawal from GLP-1 receptor agonist treatment.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with positive clinical trial progress and promising preclinical data, but also a significant increase in net loss. The sentiment is cautiously optimistic, with a focus on future potential but also acknowledging current financial challenges.

Positives

• The company has a strong cash position of $190.5 million, expected to fund operations into the second half of 2025.
• The Phase 3 SAPPHIRE trial for apitegromab in SMA is on track for a topline data readout in the fourth quarter of 2024.
• Long-term data from the TOPAZ extension study shows sustained clinical benefit and high patient retention for apitegromab in SMA.
• The EMBRAZE trial for apitegromab in obesity is enrolling ahead of schedule, indicating strong interest and efficient trial execution.
• Preclinical data for SRK-439 is promising, suggesting potential for healthier weight management.
• The company has a differentiated platform with a focus on selective targeting of latent growth factors.

Negatives

• The company reported a net loss of $58.5 million for the second quarter of 2024, which is an increase compared to the $37.9 million loss in the same quarter of 2023.
• Research and development expenses increased significantly to $42.4 million, up from $26.9 million in the prior year's quarter.
• General and administrative expenses also increased to $17.1 million from $12.2 million year-over-year.

Risks

• Clinical trial results may not be consistent with earlier data, which could impact the approval and commercialization of product candidates.
• The company is dependent on third parties for the development and manufacture of product candidates.
• There is competition from other companies developing products for similar uses.
• The company may need to obtain additional funding to support its business activities.
• The company's ability to continue as a going concern is dependent on its ability to manage expenses and obtain additional funding.

Future Outlook

The company expects to report topline data from the Phase 3 SAPPHIRE trial in the fourth quarter of 2024 and topline data from the Phase 2 EMBRAZE trial in the second quarter of 2025. They also plan to file an IND for SRK-439 in 2025 and potentially launch apitegromab in 2025 if approved.

Management Comments

• Scholar Rock continues to execute across our portfolio of highly selective myostatin inhibition programs, further cementing our position as the global leader in harnessing the life-changing potential of TGF-beta superfamily biology, said Jay Backstrom, M.D., MPH, President & Chief Executive Officer of Scholar Rock.
• With the only muscle-targeted program to demonstrate clinical proof-of-concept in SMA, our confidence in our lead program apitegromab continues to be supported by the clinical data generated over the past four years.
• The hallmark of our approach in designing both apitegromab and SRK-439 is the exquisite selectivity for proand latent forms of myostatin.
• Our year-to-date progress across our pipeline of industry-leading myostatin inhibition programs, combined with our highly experienced and disciplined team, provides us with a robust foundation for growth as we advance towards multiple milestones and our potential evolution into a commercial-stage company, said Ted Myles, Chief Operating Officer and Chief Financial Officer of Scholar Rock.

Industry Context

This announcement is relevant to the biopharmaceutical industry, particularly companies focused on developing treatments for rare diseases like SMA and cardiometabolic disorders like obesity. The progress of Scholar Rock's clinical trials and the positive preclinical data for SRK-439 are significant in the context of the growing interest in myostatin inhibition as a therapeutic approach.

Comparison to Industry Standards

• The 48-month data from the TOPAZ study showing a 5.3 point mean change in HFMSE for nonambulatory SMA patients is notable, as it demonstrates sustained improvement over a long period, which is not always seen in SMA treatments.
• The patient retention rate of over 90% in the TOPAZ study is very high, suggesting good tolerability and patient satisfaction with the treatment.
• The company's focus on selective myostatin inhibition is a differentiated approach compared to some other companies that are targeting the active form of myostatin or other related pathways.
• Companies like Sarepta Therapeutics and Biogen are also developing treatments for SMA, but Scholar Rock's approach is unique in that it is muscle-targeted.
• In the obesity space, companies like Eli Lilly and Novo Nordisk are leading with GLP-1 receptor agonists, and Scholar Rock's approach of combining myostatin inhibition with GLP-1 RAs is a novel strategy to preserve lean mass during weight loss.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss but encouraged by the clinical trial progress.
• Employees may be impacted by the increased employee-related costs.
• Patients with SMA and obesity may benefit from the potential new treatments being developed.
• Creditors may be monitoring the company's financial performance and cash runway.

Next Steps

• Report topline data from the Phase 3 SAPPHIRE trial in the fourth quarter of 2024.
• Report topline data from the Phase 2 EMBRAZE trial in the second quarter of 2025.
• File an IND for SRK-439 in 2025.
• Potentially launch apitegromab in 2025 if approved.
• Initiate a study in SMA patients younger than 2 years old in 2025.

Key Dates

Keywords

Spinal Muscular Atrophy, SMA, Obesity, Apitegromab, SRK-439, Myostatin Inhibitor, Clinical Trial, Phase 3, Phase 2, TGF-beta, Lean Mass, Cardiometabolic, Biopharmaceutical